Literature DB >> 11081539

Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system.

K S Slobod, G H Taylor, J T Sandlund, P Furth, K J Helton, J W Sixbey.   

Abstract

Epstein-Barr virus (EBV) targeted therapeutic strategies for viral associated malignant diseases have received only perfunctory consideration, first, because latent herpesviruses have been intractable to antiviral chemotherapy and, second, because the role EBV has in maintenance of the malignant cell phenotype has been uncertain. Two patients with EBV related primary central nervous system lymphoma (PCNSL) in the setting of advanced AIDS, were treated with low dose hydroxyurea based on in vitro anti-EBV activity. The responses obtained here suggest the promise of antiviral approaches in select cancers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11081539     DOI: 10.1016/S0140-6736(00)02879-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  12 in total

Review 1.  How I treat EBV lymphoproliferation.

Authors:  Helen E Heslop
Journal:  Blood       Date:  2009-09-01       Impact factor: 22.113

2.  Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screening.

Authors:  Ning Li; Scott Thompson; Hualiang Jiang; Paul M Lieberman; Cheng Luo
Journal:  Expert Opin Drug Discov       Date:  2010-12       Impact factor: 6.098

3.  Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth.

Authors:  Troy E Messick; Garry R Smith; Samantha S Soldan; Mark E McDonnell; Julianna S Deakyne; Kimberly A Malecka; Lois Tolvinski; A Pieter J van den Heuvel; Bai-Wei Gu; Joel A Cassel; Donna H Tran; Benjamin R Wassermann; Yan Zhang; Venkata Velvadapu; Edward R Zartler; Pierre Busson; Allen B Reitz; Paul M Lieberman
Journal:  Sci Transl Med       Date:  2019-03-06       Impact factor: 17.956

4.  Licking latency with licorice.

Authors:  Jeffrey I Cohen
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

5.  Development of a high-throughput screen for inhibitors of Epstein-Barr virus EBNA1.

Authors:  Scott Thompson; Troy Messick; David C Schultz; Melvin Reichman; Paul M Lieberman
Journal:  J Biomol Screen       Date:  2010-10

Review 6.  EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target.

Authors:  Keri Toner; Catherine M Bollard
Journal:  Blood       Date:  2022-02-17       Impact factor: 22.113

7.  Epstein-Barr virus episome stability is coupled to a delay in replication timing.

Authors:  Jing Zhou; Andrew R Snyder; Paul M Lieberman
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

Review 8.  Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas.

Authors:  Jeffrey I Cohen; Catherine M Bollard; Rajiv Khanna; Stefania Pittaluga
Journal:  Leuk Lymphoma       Date:  2008

Review 9.  Central nervous system infections in individuals with HIV-1 infection.

Authors:  Arunima Mamidi; Joseph A DeSimone; Roger J Pomerantz
Journal:  J Neurovirol       Date:  2002-06       Impact factor: 2.643

10.  Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated Malignancies.

Authors:  Sajal K Ghosh; Susan P Perrine; Douglas V Faller
Journal:  Adv Virol       Date:  2012-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.